Epioxa™ Copay Program
May Be Eligible To Pay As Little As
$0
for the cost of Epioxa and the corneal cross-linking procedure
Patients with commercial insurance may be eligible to pay as little as $0 out of pocket for the cost of Epioxa through the Epioxa Copay Program.
Patients with commercial insurance may also be eligible to pay as little as $0 out of pocket for the cost of the corneal cross-linking procedure.*
*Epioxa Copay Program is available for commercially insured eligible patients only. Additional restrictions may apply. Subject to change; click for full terms and conditions from EpioxaCareConnect.
Enroll your patient in EpioxaCareConnect by calling 1-855-5-EPIOXA or by visiting EpioxaCareConnect.com.
Visit EpioxaCareConnectImagine a supportive experience for your patients and your practice—that’s EpioxaCareConnect™
How will EpioxaCareConnect support your patients and practice?
EpioxaCareConnect provides centralized support services for practices, personalized patient support through Patient Access Liaisons (PALs), and in-person, field-based reimbursement support from your dedicated Reimbursement Liaison (RL).
Practice Support Through EpioxaCareConnect
- EpioxaCareConnect can perform a benefits investigation, provide prior authorization (PA) requirements, provide estimated patient out-of-pocket (OOP) costs, and determine financial assistance eligibility
- EpioxaCareConnect can also offer support through prior authorizations/pre-determinations, appeals, and peer-to-peer review
Patient Support Through Our PAL Team
- Upon enrollment in EpioxaCareConnect, each patient is paired with a dedicated PAL who offers one-on-one, non-medical support
- The PAL answers logistical questions, guides patients through insurance and access processes, and helps ensure a smooth start to treatment
- PALs stay engaged after first-eye treatment to support recovery and coordinate second-eye treatment, if needed
Reimbursement Support Through Your RL
- The RL is your field-based expert dedicated to your practice
- Provides guidance and support in interpreting payer coverage policy, documentation criteria, authorization denial support, and claim submission
- Educates HCP staff on payer trends, payment denials, and time to access
Enroll your patient in EpioxaCareConnect by calling 1-855-5-EPIOXA (1-855-537-4692) or by visiting EpioxaCareConnect.com.
Visit EpioxaCareConnectDownloadable resources
Treatment Initiation
Patient Enrollment Form
Download the form, complete it with your patient—including HCP and patient signatures—and submit it via the EpioxaCareConnect HUB or via fax.
Download enrollment formBilling and Coding
Billing and Coding Guide
A detailed resource containing billing and coding guidance, example claims forms, and other materials to support accurate billing for Epioxa.
Download guide
Billing and Coding Quick-Reference Guide
A streamlined, one-page summary of the key codes and billing pathways for quick access at the point of care.
Download guidePayer Access
Letter of Medical Necessity Template
A customizable template for a letter of medical necessity to support prior authorization for Epioxa.
Download checklist
Appeal Letter Template
A customizable appeals template for patient cases that were denied.
Download checklist
Peer-to-Peer Notepad
This tear pad is designed to help healthcare providers prepare for that conversation by organizing key clinical documentation, outlining points to address during the discussion, and taking notes during the call. Information captured should be tailored based on the provider’s clinical judgment and payer-specific requirements.
Download checklist
Peer-to-Peer Checklist
This checklist is provided for informational purposes only and is not a substitute for exercising clinical judgment. Documentation requirements may vary by payer, and providers should submit information consistent with clinical judgment and payer-specific policies. Inclusion of items in this checklist does not imply that any payer will approve coverage. The health care provider remains responsible for confirming the specific documentation and criteria required by each payer and for ensuring that the information submitted is accurate, complete, and up to date. Glaukos does not guarantee coverage or reimbursement.
Download checklistPatient Education
EpioxaCareConnect Brochure (HCP)
An overview of patient support offerings available through the EpioxaCareConnect program.
Download brochure
EpioxaCareConnect Brochure (DTC)
An overview of patient support offerings available through the EpioxaCareConnect program.
Download brochure
Insurance Explained Guide
A guide to walk your patients through insurance coverage and approval of Epioxa.
Download guide
Copay Assistance Brochure
An overview of the copay assistance program available to eligible patients with commercial insurance.
Download brochureDo you have more questions about Epioxa?
Read FAQsOur vision is innovation
We have reinvested approximately
30%
of all sales back into research and development activities to:
- Address unmet patient needs
- Deliver innovation that challenges conventional treatment paradigms
- Advance standards of care
- Improve patient lives
- Create entirely new commercial and clinical marketplaces
We’re transforming the standard of care for patients with progressive keratoconus and other corneal ectatic conditions
- Glaukos is committed to expanding the early detection and diagnosis of KC, while cultivating an interventional mindset among all eye-care providers to proactively manage the disease
- Glaukos strives to empower patients through education on KC and available treatment options, ensuring they can make informed decisions to arrest their disease and preserve their vision
- We aim to continue advancing the treatment of KC with novel technologies currently in research
Glaukos: We’ll go first
View Epioxa efficacy resultsHCP=healthcare professional; KC=keratoconus.
IMPORTANT SAFETY INFORMATION
Contraindications
EPIOXA™ HD and EPIOXA™ are contraindicated in patients with known hypersensitivity to benzalkonium chloride (BAC) or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.
Warnings and Precautions
Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.
Adverse Reactions
The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.
Dosage and Administration
EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use.
EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use.
EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only.
Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.
INDICATIONS AND USAGE
EPIOXA™ HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5’-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles®.
Please see full Prescribing Information for EPIOXA HD and EPIOXA at www.Epioxa.com.
You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
You may also call Glaukos at 1-888-404-1644.